Related Experiment Video
Updated: Mar 11, 2026

Generation of Hypoparathyroid Rats via Carbon-Nanoparticle-Assisted Parathyroidectomy
Published on: July 14, 2023
Intraperitoneal Calcitriol for Treatment of Severe Hyperparathyroidism in Children with Chronic Kidney Disease: A
Rahul Chanchlani1,2,3, Susan Ackerman1, Elizabeth Piva1
1Division of Nephrology, Department of Pediatrics, Hospital for Sick Children, University of Toronto, Toronto, Canada.
Insights
Intraperitoneal calcitriol effectively treats severe secondary hyperparathyroidism in children with chronic kidney disease on peritoneal dialysis (PD) who are resistant to oral Vitamin D. This method offers a convenient alternative for managing mineral bone disease in PD patients.
Area of Science:
- Nephrology
- Pediatric Endocrinology
- Mineral and Bone Disorders
Background:
- Chronic kidney disease (CKD) often leads to mineral bone disease (MBD) and secondary hyperparathyroidism.
- Active Vitamin D sterols are standard treatments, but oral formulations can be ineffective in children on peritoneal dialysis (PD).
- Intravenous (IV) Vitamin D is inconvenient for PD patients, prompting exploration of alternative delivery methods.
Purpose of the Study:
- To evaluate the efficacy of intraperitoneal (IP) calcitriol in treating severe secondary hyperparathyroidism in children with CKD on PD.
- To highlight IP calcitriol as a viable treatment option for PD patients refractory to oral active Vitamin D.
Main Methods:
- Case report of two children (aged 1 and 9.5 years) on chronic cycler PD with severe secondary hyperparathyroidism.
- Treatment with intraperitoneal calcitriol for 12 and 4 months, respectively.
- Review of published literature on IP calcitriol efficacy in PD patients.
Main Results:
- Successful treatment of severe secondary hyperparathyroidism in both pediatric patients.
- Demonstrated efficacy of IP calcitriol in patients resistant to oral active Vitamin D.
- IP calcitriol provided a convenient and effective therapeutic option.
Conclusions:
- Intraperitoneal calcitriol is an effective treatment for secondary hyperparathyroidism in children with CKD on PD.
- This route bypasses oral resistance and offers convenience compared to IV administration.
- Further consideration of IP calcitriol is warranted for managing MBD in PD patients.
Abstract:
Active Vitamin D sterols such as calcitriol and alfacalcidol are quite effective in the treatment of mineral bone disease secondary to chronic kidney disease. However, some children on peritoneal dialysis (PD) are resistant to oral formulations of active Vitamin D, and use of an intravenous formulation in such patients is inconvenient. In these children, intraperitoneal (IP) calcitriol has been shown to be effective in the treatment of secondary hyperparathyroidism. However, its use has declined. We report 2 children, aged 1 and 9.5 years, on chronic cycler PD with severe secondary hyperparathyroidism refractory to oral active Vitamin D who were successfully treated with IP calcitriol for a period of 12 and 4 months, respectively. We also discuss the published literature on the efficacy of IP calcitriol for treatment of secondary hyperparathyroidism and specific considerations for its use in PD patients.
Related Concept Videos
Chronic Kidney Disease III: Interprofessional Care
Urinary Tract Calculi IV: Nutrition Therapy and Prevention
Acute Kidney Injury V: Interprofessional Care
Chronic Kidney Disease IV: Nursing Management
Urinary Tract Calculi II: Pathophysiology and Clinical Manifestations
Urinary Tract Calculi III: Medical Management

